Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity

Clinical and Vaccine Immunology

Volumn 14, Issue 4, 2007, Pages 435-441

  Tedeschi, Rosamaria ^a   Pin, Elisa ^a   Martorelli, Debora ^a   Bidoli, Ettore ^a   Marus, Alessia ^a   Pratesi, Chiara ^a   Bortolin, Maria Teresa ^a   Zanussi, Stefania ^a   Vaccher, Emanuela ^a   Dolcetti, Riccardo ^a   De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; EARLY ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LATENT MEMBRANE PROTEIN 1; PROTEIN EBNA1; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; ITALY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CARCINOMA; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; NASOPHARYNGEAL NEOPLASMS; VIRUS LATENCY;

EID: 34248331339     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00466-06     Document Type: Article

References (48)

1. Bortolin, M. T., C. Pratesi, R. Dolcetti, E. Bidoli, E. Vaccher, S. Zanussi, R. Tedeschi, and P. De Paoli. 2006. Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett. 233:247-254.
2. Breslow, N. E., and N. E. Day. 1980. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Scientific Publications No. 32. International Agency for Research on Cancer, Lyon, France.
3. Chan, K. H., Y. L. Gu, F. Ng, P. S. Ng, W. H. Seto, J. S. Sham, D. Chua, W. Wei, Y. L. Chen, W. Luk, Y. S. Zong, and M. H. Ng. 2003. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma. Int. J. Cancer 105:706-709.
4. Chen, H. F., S. Kevan-Jah, K. O. Suentzenich, F. A. Grasser, and N. Mueller-Lantzsch. 1992. Expression of the Epstein-Barr virus latent membrane protein (LMP) in insect cells and detection of antibodies in human sera against this protein. Virology 190:106-115.
5. Chen, H. L., M. M. Lung, J. S. Sham, D. T. Choy, B. E. Griffin, and M. H. Ng. 1992. Transcription of BamHI-A region of the EBV genome in NPC tissues and B cells. Virology 191:193-201.
6. Cheng, H. M., Y. T. Foong, C. K. Sam, U. Prasad, and J. Dillner. 1991. Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J. Clin. Microbiol. 29:2180-2186.
7. Cheng, W. M., K. H. Chan, H. L. Chen, R. X. Luo, S. P. Ng, W. Luk, B. J. Zheng, M. F. Ji, J. S. Liang, J. S. Sham, D. K. Wang, Y. S. Zong, and M. H. Ng. 2002. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int. J. Cancer 97:489-492.
8. Chow, K. C., J. Ma, L. S. Lin, K. H. Chi, S. H. Yen, W. T. Liu, W. K. Chen, T. H. Chang, and K. Y. Chen. 1997. Serum responses to the combination of Epstein-Barr virus antigens from both latent and acute phases in nasopharyngeal carcinoma: complementary test of EBNA-1 with EA-D. Cancer Epidemiol. Biomarkers Prev. 6:363-368.
9. Dardari, R., M. Khyatti, A. Benider, H. Jouhadi, A. Kahlain, C. Cochet, A. Mansouri, B. El Gueddari, A. Benslimane, and I. Joab. 2000. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Int. J. Cancer 86:71-75.
10. Dardari, R., W. Hinderer, D. Lang, A. Benider, B. El Gueddari, I. Joab, A. Benslimane, and M. Khyatti. 2001. Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. J. Clin. Microbiol. 39:3164-3170.
11. Fachiroh, J., T. Schouten, B. Hariwiyanto, D. K. Paramita, A. Harijadi, S. M. Haryana, M. H. Ng, and J. M. Middeldorp. 2004. Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J. Infect. Dis. 190:53-62.
12. Fachiroh, J., D. K. Paramita, B. Hariwiyanto, A. Harijadi, H. L. Dahlia, S. R. Indrasari, H. Kusumo, Y. S. Zeng, T. Schouten, S. Mubarika, and J. M. Middeldorp. 2006. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J. Clin. Microbiol. 44:1459-1467.
13. Foong, Y. T., H. M. Cheng, C. K. Sam, J. Dillner, W. Hinderer, and U. Prasad. 1990. Serum and salivary IgA antibodies against a defined epitope of Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int. J. Cancer 45:1061-1064.
14. Gan, Y. Y., A. Fones Tan, S. H. Chan, and L. H. Gan. 1996. Epstein-Barr viral antigens used in the diagnosis of nasopharyngeal carcinoma. J. Biomed. Sci. 3:159-169.
15. Henle, G., and W. Henle. 1976. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer 17:1-7.
16. Hitt, M. M., M. J. Allday, T. Hara, L. Karran, M. D. Jones, P. Busson, T. Tursz, I. Ernberg, and B. E. Griffin. 1989. EBV gene expression in an NPC-related tumour. EMBO J. 8:2639-2651.
17. Ho, S. Y., Y. J. Wang, P. C. Huang, S. T. Tsai, C. H. Chen, H. H. Chen, C. J. Chang, and H. R. Guo. 2006. Evaluation of the associations between the single nucleotide polymorphisms of the promoter region of the tumor necrosis factor-alpha gene and nasopharyngeal carcinoma. J. Chin. Med. Assoc. 69:351-357.
18. Huang, Y. T., T. S. Sheen, C. L. Chen, J. Lu, Y. Chang, J. Y. Chen, and C. H. Tsai. 1999. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res. 59:1599-1605.
19. Joab, I., H. Triki, J. de Saint Martin, M. Perricaudet, and J. C. Nicolas. 1991. Detection of anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus. J. Infect. Dis. 163:53-56.
20. Joab, I., J. C. Nicolas, G. Schwaab, G. de-The, B. Clausse, M. Perricaudet, and Y. Zeng. 1991. Detection of anti-Epstein-Barr virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int. J. Cancer 48:647-649.
21. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387-405.
22. Littler, E., S. A. Baylis, Y. Zeng, M. J. Conway, M. Mackett, and J. R. Arrand. 1991. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337:685-689.
23. Liu, M. Y., Y. L. Chang, J. Ma, H. L. Yang, M. M. Hsu, C. J. Chen, J. Y. Chen, and C. S. Yang. 1997. Evaluation of multiple antibodies to Epstein-Barr virus as markers for detecting patients with nasopharyngeal carcinoma. J. Med. Virol. 52:262-269.
24. Liu, M. Y., Y. T. Huang, T. S. Sheen, J. Y. Chen, and C. H. Tsai. 2004. Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma. J. Med. Virol. 73:574-582.
25. Mathew, A., H. M. Cheng, C. K. Sam, I. Joab, U. Prasad, and C. Cochet. 1994. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma. Cancer Immunol. Immunother. 38:68-70.
26. Meij, P., M. B. Vervoort, J. Aarbiou, van P. Dissel, A. Brink, E. Bloemena, C. J. Meijer, and J. M. Middeldorp. 1999. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases. J. Infect. Dis. 179:1108-1115.
27. Meij, P., M. B. Vervoort, E. Bloemena, T. E. Schouten, C. Schwartz, S. Grufferman, R. F. Ambinder, and J. M. Middeldorp. 2002. Antibody responses to Epstein-Barr virus-encoded latent membrane protein-1 (LMP1) and expression of LMP1 in juvenile Hodgkin's disease. J. Med. Virol. 68:370-377.
28. Menezes, J., W. Leibold, G. Klein, and G. Clements. 1975. Establishment and characterization of an Epstein-Barr virus (EBV)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine 22:276-284.
29. Modrow, S., and H. Wolf. 1986. Characterization of two related Epstein-Barr virus encoded membrane proteins that are differentially expressed in Burkitt lymphoma and in vitro transformed cell lines. Proc. Natl. Acad. Sci. USA 83:5703-5707.
30. Ng, M. H., H. L. Chen, R. X. Luo, K. H. Chan, P. C. Woo, J. S. Sham, J. Huang, W. H. Seto, P. Smith, and B. E. Griffin. 1998. Serological diagnosis of nasopharyngeal carcinoma by enzyme linked immunosorbent assay optimization, standardization and diagnostic criteria. Chin. Med. J. 111:531-536.
31. Rickinson, A. B., and D. J. Moss. 1997. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu. Rev. Immunol. 15:405-431.
32. Rowe, M., J. Finke, R. Szigeti, and G. Klein. 1988. Characterization of serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J. Gen. Virol. 69:1217-1228.
33. Sanguineti, G., F. B. Geara, A. S. Garden, S. L. Tucker, K. K. Ang, W. H. Morrison, and L. J. Peters. 1997. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int. J. Radiat. Oncol. Biol. Phys. 37:985-996.
34. Shao, J. Y., Li, Y. H., H. Y. Gao, Q. L. Wu, N. J. Cui, L. Zhang, G. Cheng, L. F. Hu, I. Ernberg, and Y. X. Zeng. 2004. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 100:1162-1170.
35. Stavnezer, J. 1995. Regulation of antibody production and class switching by TGF-beta. J. Immunol. 155:1647-1651.
36. Stevens, S. J., S. A. Verkuijlen, B. Hariwiyanto, Harijadi, J. Fachiroh, D. K. Paramita, I. B. Tan, S. M. Haryana, and J. M. Middeldorp. 2005. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J. Clin. Microbiol. 43:3066-3073.
37. Sulitzeanu, D., R. Szigeti, A. Hatzubai, J. Dillner, M. L. Hammarskjold, G. Klein, and E. Klein. 1988. Antibodies in human sera against the Epstein-Barr virus encoded latent membrane protein (LMP). Immunol. Lett. 18:301-306.
38. Tan, E. L., G. Selvaratnam, R. Kananathan, and C. K. Sam. 2006. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. BMC Cancer 6:227.
39. Tedeschi, R., Y. T. Foong, H. M. Cheng, P. de Paoli, T. Lehtinen, T. Elfborg, and J. Dillner 1995. The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J. Gen. Virol. 76:1393-1400.
40. Tsang, R. K., A. C. Vlantis, R. W. Ho, J. S. Tam, K. F. To, and C. A. van Hasselt. 2004. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck 26:598-602.
41. van Grunsven, W. M., A. Nabbe, and J. M. Middeldorp. 1993. Identification and molecular characterization of two diagnostically relevant marker proteins of the Epstein-Barr virus capsid antigen complex. J. Med. Virol. 40:161-169.
42. van Grunsven, W. M., W. J. Spaan, and J. M. Middeldorp. 1994. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein. J. Infect. Dis. 170:13-19.
43. Walling, D. M., C. M. Flaitz, C. M. Nichols, S. D. Hundnall, and K. Adler-Storthz. 2001. Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. J. Infect. Dis. 184:1499-1507.
44. Xu, J., A. Ahmad, M. D'Addario, L. Knafo, J. F. Jones, U. Prasad, R. Dolcetti, E. Vaccher, and J. Menezes. 2000. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J. Immunol. 164:2815-2822.
45. Yip, T. T., R. K. Ngan, W. H. Lau, Y. F. Poon, I. Joab, C. Cochet, and A. K. Cheng. 1994. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74:2414-2424.
46. Zanussi, S., E. Vaccher, C. Caffau, C. Pratesi, C. Crepaldi, M. T. Bortolin, R. Tedeschi, D. Politi, L. Barman, U. Tirelli, and P. De Paoli. 2003. Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol. Immunother. 52:28-32.
47. Zeng, Y., J. M. Zhong, L. Y. Li, P. Z. Wang, H. Tang, Y. R. Ma, J. S. Zhu, W. J. Pan, Y. X. Liu, Z. N. Wei, et al. 1983. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology 20:190-194.
48. Zhang, J. X., H. L. Chen, Y. S. Zong, K. H. Chan, J. Nicholls, J. M. Middeldorp, J. S. Sham, B. E. Griffin, and M. H. Ng. 1998. Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J. Med. Virol. 55:227-233.